Summary of Key Points
British pharmaceutical company AstraZeneca is in negotiations to merge with American company Bristol-Myers Squibb. If successful, it would be the largest merger in the history of the global pharmaceutical industry, with annual sales exceeding $100 billion, directly surpassing giants such as Johnson & Johnson and Pfizer to become the number one in the world. However, the market is not optimistic about this move: AstraZeneca's stock price plummeted by 7.9% after the news was announced, while Bristol-Myers Squibb only rose slightly by 0.24%. The reasons behind this include the extreme difficulty of the transaction (both companies cannot afford each other outright; a complex exchange of shares and debt financing are required, plus there may be antitrust scrutiny), as well as high integration risks.
Additionally, AstraZeneca nearly fell into the same situation as Bristol-Myers Squibb due to a "patent cliff" and turned things around through research and development reforms. Bristol-Myers Squibb is currently facing a similar patent crisis, with a market value only half that of AstraZeneca, which could be why AstraZeneca is considering this merger as an opportunity to buy low, but there are also many uncertainties.
How Significant Is This Merger?
If the merger goes through, the combined annual sales of the two companies would reach $106.9 billion ($58.7 billion from AstraZeneca and $48.2 billion from Bristol-Myers Squibb), exceeding the current global leader Johnson & Johnson's $94.2 billion by more than $10 billion, making them the first pharmaceutical company with annual sales in the tens of billions.
Both companies possess a number of blockbuster drugs: AstraZeneca has treatments for lung cancer such as Tagrisso and Imfinib, as well as the diabetes drug Dapagliflozin; Bristol-Myers Squibb has immunotherapy drugs like Opdivo and anticoagulants like Eliquis. The merger would bring together the industry's "top weapons," covering areas such as oncology, cardiovascular diseases, kidney diseases, and rare disorders.
However, this is an exceptionally large-scale merger. In the past, pharmaceutical acquisitions have mostly involved amounts in the billions, such as Bristol-Myers Squibb's $74 billion acquisition of Novartis in 2019 and AstraZeneca's $39 billion acquisition of Alexion in 2020, which pales in comparison.
Why Is the Market Unimpressed?
The market is skeptical mainly because of the difficulties involved in the transaction and the high integration risks:
1. Lack of funds: Both companies have significant market values (AstraZeneca $260 billion, Bristol-Myers Squibb $130 billion), but neither has enough cash to acquire the other outright. The merger would require an exchange of shares and substantial debt financing, making it highly complex and prone to issues.
2. Antitrust concerns: The products of both companies overlap in many areas (e.g., oncology and cardiovascular diseases), which could lead to market monopolies, and regulatory authorities are likely to block such a merger.
3. Integration challenges: AstraZeneca has been performing well recently and is considered a model of organic growth in the industry, while Bristol-Myers Squibb, despite its high current revenue, faces patent issues. The cultures, R&D systems, and sales networks of the two companies are different, so it's uncertain whether they can integrate effectively.
AstraZeneca: From Nearly Being Sold to Aspiring to Be the Leader
Twelve years ago, AstraZeneca was an "endangered" company with annual sales of $33.6 billion, which dropped to $22.1 billion by 2018 due to a "patent cliff" (the expiration of core drug patents and the entry of generic drugs into the market). In 2014, Pfizer offered to acquire AstraZeneca for $117 billion, but the management rejected the offer.
AstraZeneca turned things around through two key reforms:
- R&D optimization: They established a "5R framework" (identifying the right targets, ensuring the drug is effective, being safe, targeting the right patients, and having market potential), and eliminated ineffective projects early on, saving millions of dollars.
- Focusing on core areas: They shifted their focus from trying to cover all areas to focusing on oncology, cardiovascular diseases, respiratory immunology, and rare disorders, with mature drugs in each area and a pipeline of new drugs.
As a result, AstraZeneca's sales in 2023 reached $45.8 billion, exceeding its targets, and its market value has more than doubled, making it highly sought after by investors. With this merger, AstraZeneca aims to leverage Bristol-Myers Squibb's U.S. market resources (the largest pharmaceutical market in the world) to accelerate its expansion and enhance its product portfolio.
Bristol-Myers Squibb: Currently Successful, but Facing a Future Patent Cliff
Bristol-Myers Squibb has high revenue ($48.2 billion in 2025), but its market value is only half that of AstraZeneca because it is also facing a patent crisis:
- Half of its revenue comes from two blockbuster drugs, Eliquis and Opdivo, whose U.S. patents will expire around 2028. Once the patents expire, generic versions will enter the market, potentially causing a sharp decline in revenue (genetic drugs are often easier to copy, leading to faster declines in sales).
- Although Bristol-Myers Squibb has new drug candidates like Milvexian, it's uncertain whether they will be successful. Therefore, AstraZeneca's interest in merging could be seen as an attempt to buy low, using its valuable shares for Bristol-Myers Squibb's U.S. market and product portfolio, but there is also the risk that the new drugs may not perform as expected, potentially dragging down the merged company.
The Real Reason Behind Mergers in the Pharmaceutical Industry
The key reason for mergers is the "patent cliff": Drug patents typically last 20 years, and once they expire, generic versions enter the market, causing a significant drop in revenue. Pharmaceutical companies must either invest heavily in R&D (with high risks and long timelines) or acquire existing product portfolios through mergers.
AstraZeneca is both investing in its own R&D (for organic growth) and acquiring companies (e.g., purchasing Chinese company Genexin for $1.2 billion in 2023). Bristol-Myers Squibb, facing upcoming patent expiries, needs a partner to support its future product development. Even giants like Johnson & Johnson frequently rely on mergers to strengthen their portfolios.
In essence, all pharmaceutical companies are concerned about the "patent cliff" because drugs that perform well today may become less profitable tomorrow. Mergers are a common strategy to mitigate these risks and expand market share, but they also carry significant risks, as failure could result in both financial losses and strategic setbacks.
Whether this merger will actually happen is still uncertain, but it highlights the core concerns of the pharmaceutical industry: even becoming the global leader, companies must constantly worry about their future revenue streams. For consumers, another question is whether prices will increase after the merger, as monopolies may lead to higher pricing, or whether scale effects will reduce costs. The ultimate outcome will depend on regulatory authorities and market dynamics.